Goldman Sachs(US:GS) 智通财经网·2025-11-11 06:59Core Insights - The healthcare sector's decline presents stock-picking opportunities, but an overall rebound is unlikely [1] - Year-to-date, the healthcare sector (XLV) has underperformed the S&P 500 by 8 percentage points and is on track to underperform for the third consecutive year [1] - Despite low valuations indicating potential upside, robust economic growth, the AI boom, and policy uncertainties may limit overall sector performance [1] - Alpha opportunities are seen as greater than beta returns, with increasing return rate disparities and active M&A activity in the healthcare sector driving stock selection [1] - Goldman Sachs expects M&A activity to continue growing into next year, with nearly half of its M&A concept stock portfolio consisting of healthcare companies [1] Stock Selection - Goldman Sachs has identified specific healthcare stocks from the Russell 1000 index that have recently seen upward revisions in 2026 EPS forecasts and are currently valued below historical levels [2] - Selected stocks include: Jazz Pharmaceuticals (JAZZ.US), Insulet (PODD.US), Sotera Health (SHC.US), Incyte (INCY.US), Regeneron Pharmaceuticals (REGN.US), Biomarin Pharmaceutical (BMRN.US), Universal Health Services (UHS.US), Doximity (DOCS.US), Endocrine Biosciences (NBIX.US), Vertex Pharmaceuticals (VRTX.US), Illumina (ILMN.US), West Pharmaceutical Services (WST.US), DaVita (DVA.US), Edwards Lifesciences (EW.US), Eli Lilly (LLY.US), Zimmer Biomet Holdings (ZBH.US), Penumbra (PEN.US), Nevro (NVST.US), Medtronic (MDT.US), Veeva Systems (VEEV.US), Masimo (MASI.US), Pfizer (PFE.US), Thermo Fisher Scientific (TMO.US), ResMed (RMD.US), Bio-Rad Laboratories (BIO.US), Certara (CERT.US), Align Technology (ALGN.US), Charles River Laboratories International (CRL.US), and Hologic (HOLX.US) [2]